.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Farmers Insurance
Johnson and Johnson
Daiichi Sankyo
Deloitte
Harvard Business School
Citi
Cipla
Teva
Queensland Health

Generated: July 27, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 077805

« Back to Dashboard
NDA 077805 describes TRANDOLAPRIL, which is a drug marketed by Watson Labs, Cipla, Epic Pharma, Invagen Pharms, Lupin, Aurobindo Pharma, Mylan, Epic Pharma Llc, Teva Pharms, Dr Reddys Labs Ltd, and Glenmark Generics, and is included in eleven NDAs. It is available from eight suppliers. Additional details are available on the TRANDOLAPRIL profile page.

The generic ingredient in TRANDOLAPRIL is trandolapril; verapamil hydrochloride. There are ten drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the trandolapril; verapamil hydrochloride profile page.

Summary for NDA: 077805

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 077805

Suppliers and Packaging for NDA: 077805

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRANDOLAPRIL
trandolapril
TABLET;ORAL 077805 ANDA Actavis Pharma, Inc. 16252-541 16252-541-30 30 TABLET in 1 BOTTLE, PLASTIC (16252-541-30)
TRANDOLAPRIL
trandolapril
TABLET;ORAL 077805 ANDA Actavis Pharma, Inc. 16252-542 16252-542-90 90 TABLET in 1 BOTTLE, PLASTIC (16252-542-90)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength1MG
Approval Date:Jun 12, 2007TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2MG
Approval Date:Jun 12, 2007TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength4MG
Approval Date:Jun 12, 2007TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Colorcon
Baxter
McKesson
Fuji
Harvard Business School
AstraZeneca
US Department of Justice
Daiichi Sankyo
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot